New hope for older leukemia patients: targeted pill shows promise
NCT ID NCT01500733
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II study tests a daily pill called PCI-32765 (ibrutinib) in 86 people with chronic lymphocytic leukemia or small lymphocytic lymphoma who are over 65 or have a specific genetic change (17p deletion). These groups often do not respond well to standard chemotherapy. Participants take the drug for 28-day cycles, and the study measures how many achieve a complete or partial response after six months. The goal is to see if this targeted therapy is safe and effective for these hard-to-treat patients.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- PCI-32765 (ibrutinib)
- What this could lead to
- If successful, this could provide a well-tolerated, effective treatment option for older CLL/SLL patients and those with a 17p deletion who do not respond well to standard chemotherapy.
- What could go wrong
- This is a phase II trial with only 86 participants, so results may not apply to all patients. Side effects from ibrutinib can include bleeding, infection, and heart rhythm problems.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLL (CHRONIC LYMPHOCYTIC LEUKEMIA) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New PET tracer could sharpen diagnosis of blood cancers
- 10,000 DNA samples could reveal hidden genetic triggers for leukemia and lymphoma
- Could bone marrow from deceased donors cure blood cancers?
- New dashboard aims to make leukemia trials more inclusive
- Gene mapping of childhood blood cancers could unlock personalized treatments
- Could an ALS drug clear the fog of chemo brain?